Status:
RECRUITING
Mixed Molecular Clinical Index (MMCI) in Diffuse Large B-cell Lymphoma (DLBCL)
Lead Sponsor:
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Conditions:
Diffuse Large B Cell Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
This is a prospective and retrospective observational study. The primary objective is to identify new prognostic biomarkers for DLBCL patients in terms of progression-free survival (PFS) and able to a...
Detailed Description
Diffuse large B-cell lymphoma (DLBCL) is an heterogeneous group of cancers classified together on the basis of morphology, immunophenotype, genetic alterations and clinical behavior. The distinction o...
Eligibility Criteria
Inclusion
- Inclusion Criteria for the prospective cohort:
- New diagnosis of High grade Diffuse large B cell Lymphoma undergoing first line standard treatment;
- Signed written informed consent;
- Availability of FFPE sample.
- Inclusion Criteria for the retrospective cohort:
- Diagnosis of High grade Diffuse large B cell Lymphoma from 2011 to 2017;
- Availability of FFPE sample and clinical data.
- Exclusion Criteria:
- Patients included in clinical trials.
Exclusion
Key Trial Info
Start Date :
May 14 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2028
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04300101
Start Date
May 14 2020
End Date
May 1 2028
Last Update
April 10 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Irst Irccs
Meldola, FC, Italy, 47014
2
Ospedale S. Maria delle Croci RAVENNA
Ravenna, RA, Italy, 48121
3
L'Azienda Ospedaliero-Universitaria Di Bologna Policlinico S. Orsola-Malpighi
Bologna, Italy
4
Ospedale Infermi
Rimini, Italy, 47924